Candel Therapeutics Inc. (CADL)
NASDAQ: CADLHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
CADL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $751.41M
- EPS (TTM)
- -$1.45
- Dividend yield
- None
- 52-week range
- 4.35 – 14.00
- Day range
- 9.60 – 9.94
- Volume / Avg
- 714.93K / 1.23M
- Beta
- —
- Shares outstanding
- 76.52M
52-week range
CADL stock today
Candel Therapeutics (CADL) closed at $9.82 on Oct 7, down 0.51% (-$0.05), versus the S&P 500's 0.22% decline. At this level, CADL sits in the middle of its 52-week range of $4.35 to $14.00: 29.9% below the high, set on Aug 27, 2026 and 125.7% above the low. CADL is up 73.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 74.4%.
Candel Therapeutics has posted a net loss over the last twelve months (EPS of -$1.45), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Candel Therapeutics
Company profileCandel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
- Headquarters
- Needham, MA
- Employees
- 55
- IPO year
- 2021
- Website
- candeltx.com
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$21.75+121.49%
- Strong buy 0
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
CADL news
All CADL newsCandel Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| APMDApnimed Inc. | 18.04 | -3.27% | $751.02M | vs CADL |
| ANNXAnnexon Inc. | 4.01 | -0.50% | $760.21M | vs CADL |
| ATTOAttovia Therapeutics Inc. | 16.42 | -6.17% | $749.59M | vs CADL |
| VSTMVerastem Inc. | 8.27 | +6.65% | $748.51M | vs CADL |
| GYREGyre Therapeutics Inc. | 7.04 | -0.56% | $746.48M | vs CADL |
| ACHVAchieve Life Sciences Inc. | 7.24 | +2.99% | $746.46M | vs CADL |
| HELPHelus Pharma Inc. | 10.51 | -2.32% | $767.86M | vs CADL |
| GERNGeron Corporation | 1.20 | -0.83% | $770.97M | vs CADL |
Indexes, lists and sector
Appears in lists
Candel Therapeutics stock FAQ
What is Candel Therapeutics's stock price today?
CADL last traded at $9.82 as of Oct 7, 4:00 PM EDT, down 0.51% on the day. Prices are delayed at least 15 minutes.
Who is Candel Therapeutics's CEO?
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. is the chief executive officer of Candel Therapeutics Inc., which has about 55 employees.
What is the CADL 52-week high?
The 52-week high for CADL is $14.00 and the 52-week low is $4.35. The stock is currently 29.9% below its high.